创新药企谁能走出冬天？《投资者网》蔡俊荣昌生物（688331.SH、09995.HK，下称“公司”）在一个新阶段，再度出手。这一次，公司仍以出海为切入口。在业绩增长、亏损收窄的背景下，公司的资金压力犹存，并试图推动资本化再次寻求融资。更为重要的，同行创新药企已有部分走出寒冬，而公司历经自己的高光时刻后，面对更大的竞争压力，做出了自己的路径抉择。反差的背后6月底，公司的BD交易揭开面纱。根据公告，...
Source Link创新药企谁能走出冬天？《投资者网》蔡俊荣昌生物（688331.SH、09995.HK，下称“公司”）在一个新阶段，再度出手。这一次，公司仍以出海为切入口。在业绩增长、亏损收窄的背景下，公司的资金压力犹存，并试图推动资本化再次寻求融资。更为重要的，同行创新药企已有部分走出寒冬，而公司历经自己的高光时刻后，面对更大的竞争压力，做出了自己的路径抉择。反差的背后6月底，公司的BD交易揭开面纱。根据公告，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.